Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VALN
VALN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VALN News
Valneva Updates Ixchiq Vaccine Recommendations in the UK
2d ago
seekingalpha
UK Updates IXCHIQ Vaccine Usage Recommendations
2d ago
Newsfilter
Valneva and Brazil Launch Pilot Chikungunya Vaccine Program
Feb 03 2026
Newsfilter
Valneva Withdraws Ixchiq Vaccine Applications Amid FDA Hold
Jan 20 2026
Benzinga
Valneva SE Withdraws Chikungunya Vaccine Applications, Shares Drop 7.7%
Jan 20 2026
Benzinga
Valneva SE Withdraws IXCHIQ Vaccine Applications Following FDA License Suspension
Jan 20 2026
NASDAQ.COM
Valneva Withdraws IXCHIQ Vaccine Applications Following FDA Suspension
Jan 19 2026
Globenewswire
Valneva to Showcase Vaccine Progress at J.P. Morgan Conference
Jan 09 2026
Globenewswire
Valneva to Showcase Vaccine Progress at J.P. Morgan Conference
Jan 09 2026
Yahoo Finance
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Valneva (VALN) Ends Licensing Deal with Serum Institute of India
Dec 31 2025
Yahoo Finance
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Dec 15 2025
NASDAQ.COM
Valneva Reports Positive Phase 2 Results for IXCHIQ® Chikungunya Vaccine in Children, Supporting Future Phase 3 Trials
Dec 10 2025
Globenewswire
Valneva Reports Positive Phase 2 Data for IXCHIQ® Chikungunya Vaccine in Children, Supporting Future Phase 3 Trials
Dec 10 2025
Newsfilter
Valneva reduces R&D operations by closing its French facility
Nov 27 2025
Yahoo Finance
Valneva Reports Encouraging Results for Lyme Vaccine Booster as Pfizer Aims for 2026 Regulatory Submissions
Nov 26 2025
Benzinga
Show More News
